Decro Pharma Private Limited, a active private limited company, was established on 21 October 2020 in Indrad, Gujarat, India. Engaging in industrial chemicals within the manufacturing sector, it holds CIN: U24210GJ2020PTC117562. Registered under ROC Roc Ahmedabad. it is unlisted. It has an authorized capital of ₹6.50 Cr and a paid-up capital of ₹6.50 Cr.
It upholds a compliant status. Its leadership includes Sangitaben Rakeshkumar Patel (Director), Rakesh Ambalal Patel (Director), Arvindbhai Patel (Director). Past directors included Sangitaben Rakeshkumar Patel, Arvindbhai Patel. It holds ₹38.80 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at New Survey No.- 466, Plot No 7, Umiya Industrial Estate, Ta. Kadi,, Indrad, Gujarat, 382715.
U24210GJ2020PTC117562
117562
21 October 2020
₹6.50 Cr
₹6.50 Cr
Roc Ahmedabad
Unlisted
Active
Explore comprehensive insights into Decro Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sangitaben Rakeshkumar Patel | Director | 08 May 2021 | Current |
| Rakesh Ambalal Patel | Director | 21 Oct 2020 | Current |
| Arvindbhai Patel | Director | 08 May 2021 | Current |
| Bhikan Nimba Patil | Director | 21 Oct 2020 | Current |
| Narendra Rajdev Pandey | Director | 21 Oct 2020 | Current |
| Hareshbhai Kalabhai Patel | Director | 21 Oct 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Nov 2021 | Past |
| Pramod Abcsdd | Additional Director | 30 Nov 2021 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Decro Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 3390.18% increase. The company also saw a substantial improvement in profitability, with a 4628% increase in profit. The company's net worth Soared by an impressive increase of 53598.64%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Decro Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹388,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Mar 2022 | State Bank Of India | ₹19.40 Cr | Open |
| 30 Mar 2022 | State Bank Of India | ₹19.40 Cr | Open |
Explore comprehensive loan charge details -
Decro Pharma has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Decro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Decro Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Decro Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
A charge with State Bank Of India of Rs. 19.40 Cr registered on 30 Mar 2022 with Charge ID 100568091 was modified on 26 Apr 2024. was recorded as a recent event.
A charge with State Bank Of India of Rs. 19.40 Cr registered on 30 Mar 2022 with Charge ID 100567876 was modified on 26 Apr 2024. was recorded as a recent event.
Decro Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ahmedabad. was recorded as a recent event.
The activity A charge with State Bank Of India amounted to Rs. 19.40 Cr with Charge ID 100568091 was registered on 30 Mar 2022. was completed.
Progress on A charge with State Bank Of India amounted to Rs. 19.40 Cr with Charge ID 100567876 was registered on 30 Mar 2022. was documented.
The CIN of Decro Pharma Private Limited is U24210GJ2020PTC117562.
Decro Pharma Private Limited is headquartered at New Survey No.- 466, Plot No 7, Umiya Industrial Estate, Ta. Kadi,, Indrad, Gujarat, 382715.
Decro Pharma Private Limited was incorporated on 21 October 2020.
The current directors of Decro Pharma Private Limited are
The primary industry of Decro Pharma Private Limited is Manufacturing.
Decro Pharma Private Limited is unlisted.
The authorized capital of Decro Pharma Private Limited is ₹6.50 Cr, and the paid-up capital is ₹6.50 Cr.
The compliance status of Decro Pharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX